Anixa Biosciences logo
Anixa Biosciences ANIX
$ 2.83 -4.39%

Annual report 2025
added 01-12-2026

report update icon

Anixa Biosciences Financial Statements 2011-2026 | ANIX

Annual Financial Statements Anixa Biosciences

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

104 K 70.8 K 151 K 137 K 60.1 M 58.7 M 75.8 M 69.1 M 30.5 M 54.7 M 27 M 40.7 M 45.4 M 39.9 M 23.8 M

Shares

32.5 K 31.9 K 31 K 30.4 K 30.1 M 22.2 M 19.8 M 17.6 M 12.2 M 9.6 M 9.63 M 9.57 M 8.64 M 7.98 M 7.33 M

Historical Prices

3.19 2.22 4.87 4.52 2.97 3.07 3.28 3.94 2.36 5.4 3.01 2.75 4.75 4.5 2.75

Net Income

-10.9 M -12.6 M -9.81 M -13.6 M -13 M -10.1 M -11.6 M -14 M -5.01 M -5.02 M -1.38 M -9.61 M -10.1 M -4.25 M -7.38 M

Revenue

- - 210 K - 512 K - 250 K 1.11 M 362 K 300 K 9.26 M 3.67 M 389 K 947 K 1 M

Gross Profit

- - - - - - 83.8 K 344 K 258 K 82.6 K 5.61 M 1.68 M 72.2 K 943 K 969 K

Operating Income

-11.7 M -13.8 M -11 M -13.9 M -13.1 M -9.98 M -11.9 M -14.3 M -6.08 M -4.51 M -945 K -5.04 M -7.92 M -4.13 M -5.03 M

Interest Expense

- - - - - - - - 500 K 520 K 452 K 1.26 M 1.11 M 7.66 K -

EBITDA

-11.7 M -13.8 M -11 M -13.9 M -13.1 M -9.94 M -11.1 M -13.4 M -5.75 M -4.18 M -619 K -4.73 M -7.92 M -4.13 M -5.02 M

Operating Expenses

- - - - - 9.98 M 11.6 M 14.1 M 6.33 M 4.59 M 6.55 M 6.72 M 7.99 M 5.08 M 6 M

General and Administrative Expenses

6.63 M 7.44 M 6.29 M 7.17 M 7.07 M 5.6 M 5.66 M 6.91 M 4.41 M 2.71 M 6.23 M 6.41 M 7.99 M - -

All numbers in USD currency

Quarterly Income Statement Anixa Biosciences

2025-Q2 2025-Q1 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

32.5 M 32.2 M 32.2 M 32.1 M 31.9 M 31.4 K 31.1 M 31 K 30.9 K 30.9 K 30.9 M 30.5 K 30.2 M 25.2 M 30.1 M 30.5 M 28.7 M 20.7 M 21.7 M 23.2 M 21.2 M 19.2 M 19.6 M 20.1 M 19.6 M 16.6 M 17.3 M 18.4 M 16.7 M 8.76 M 11 M 14.6 M 9.73 M 8.73 M 8.74 M 8.75 M 8.74 M 8.79 M 8.77 M 8.76 M 8.77 M 210 M 8.62 M 8.93 M 213 M 185 M 193 M 202 M 192 M 178 M 181 M 183 M 181 M - 164 M 171 M 166 M

Net Income

-2.26 M -2.79 M - -3.28 M -3.14 M -3.26 M - -2.51 M -2.29 M -2.32 M -10.1 M -2.75 M -3.54 M -2.21 M -8.94 M -4.33 M -2.4 M -2.59 M -7.79 M -2.56 M -2.64 M -4.97 M -9.56 M -2.14 M -2.57 M -1.84 M -8.85 M -5.48 M -1.38 M -3.6 M -3.22 M -1.79 M 160 K -1.59 M -3.97 M -1.1 M -1.27 M 3.75 M -86.6 K -1.6 M -2.24 M -3.61 M -6.45 M 411 K -3.25 M -2.09 M -7.15 M -2.58 M -2.48 M -886 K -1.86 M -629 K -877 K -1.53 M -2.79 M -1.77 M -1.29 M

Revenue

- - - - - - - - 210 K 513 K - - - 512 K 513 K 513 K - - - - - - 250 K 250 K 250 K - 1.11 M 362 K 750 K - 362 K 362 K - - 100 K 100 K - 9.14 M 9.26 M 95 K 25 K - 2.29 M 1.19 M 1.1 M 2.13 K - - - 449 K 350 249 K 248 K 17 K 449 K 450 K 86.9 K

Cost of Revenue

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 595 K - - 2.84 M 1.09 M -

Operating Income

-2.44 M -3 M - -3.59 M -3.47 M -3.61 M - -2.84 M -2.56 M -2.56 M -10.3 M -2.8 M -3.59 M -2.23 M -9.06 M -4.39 M -2.44 M -2.63 M -7.74 M -2.44 M -2.67 M -4.98 M -9.76 M -2.18 M -2.59 M -1.87 M -8.88 M -5.61 M -1.4 M -1.39 M -4.34 M -1.73 M -1.21 M -1.47 M -3.6 M -975 K -1.15 M 3.86 M 233 K -1.49 M -2.13 M -1.96 M -3.48 M -160 K -1.36 M -2.07 M -6.14 M -2.22 M -1.85 M -887 K -2.41 M -643 K -878 K -1.53 M -4.02 M -1.21 M -1.29 M

Interest Expense

- - - - - - - - - - - - - - - - - - - 7.27 K - - 53.8 K 18.4 K - - - - - 195 K 443 K 71.7 K 176 K 124 K 383 K 132 K 127 K 109 K 334 K 116 K 109 K 379 K 1.08 M 281 K 422 K 22.2 K 983 K 125 K 835 K - - - - - - - -

EBITDA

- - - - - - - - - -2.56 M -10.3 M -2.8 M -3.59 M -2.23 M -9.06 M -4.39 M -2.44 M -2.61 M -7.7 M -2.41 M -2.67 M -4.98 M -9.73 M -2.17 M -2.47 M -1.87 M -8.87 M -5.6 M -1.32 M -1.38 M -4.31 M -1.71 M -1.13 M -1.47 M -3.57 M -961 K -1.07 M 3.86 M 477 K -1.41 M -2.05 M -1.89 M -3.25 M -78.3 K -1.27 M -2.07 M -6.14 M -2.22 M -1.85 M -885 K -2.41 M -643 K -878 K -1.52 M -4.02 M -1.2 M -1.29 M

General and Administrative Expenses

1.38 M 1.68 M - 1.67 M 1.82 M 2.26 M - 1.76 M 1.61 M 1.49 M 5.25 M 1.35 M 1.85 M 1.53 M 5.17 M 2.22 M 1.42 M 1.14 M 3.76 M 1.18 M 1.44 M 2.07 M 4.41 M 1.06 M 1.28 M 990 K 4.6 M 2.7 M 909 K 860 K 3.07 M 1.51 M 699 K 873 K 2.16 M 631 K 659 K 1.77 M 5.15 M 1.42 M 1.96 M 1.86 M 4.81 M 1.1 M 1.84 M 2.07 M 6.12 M 2.2 M 1.84 M 686 K 1.64 M 434 K 522 K 761 K 2.15 M 775 K 618 K

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Anixa Biosciences ANIX
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Anixa Biosciences plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Diagnostics research industry

Issuer Price % 24h Market Cap Country
Centogene N.V. Centogene N.V.
CNTG
- -6.23 % $ 30.6 M germanyGermany
Agilent Technologies Agilent Technologies
A
$ 115.87 -1.95 % $ 35.2 B usaUSA
Castle Biosciences Castle Biosciences
CSTL
$ 27.47 -1.86 % $ 763 M usaUSA
Fulgent Genetics Fulgent Genetics
FLGT
$ 13.81 -2.78 % $ 418 M usaUSA
Celcuity Celcuity
CELC
$ 105.83 -2.29 % $ 4.17 B usaUSA
Akumin Akumin
AKU
- -17.87 % $ 25.9 M canadaCanada
ICON Public Limited Company ICON Public Limited Company
ICLR
$ 105.3 -2.75 % $ 8.69 B irlandaIrlanda
IDEXX Laboratories IDEXX Laboratories
IDXX
$ 642.42 0.9 % $ 51.7 B usaUSA
Illumina Illumina
ILMN
$ 128.6 -3.23 % $ 20.4 B usaUSA
Oxford Immunotec Global PLC Oxford Immunotec Global PLC
OXFD
- - $ 562 M britainBritain
Charles River Laboratories International Charles River Laboratories International
CRL
$ 174.83 -2.12 % $ 8.67 B usaUSA
Laboratory Corporation of America Holdings Laboratory Corporation of America Holdings
LH
$ 280.01 -2.26 % $ 23.3 B usaUSA
Lantheus Holdings Lantheus Holdings
LNTH
$ 77.75 1.9 % $ 5.25 B usaUSA
Aspira Women's Health Aspira Women's Health
AWH
- -6.19 % $ 10.5 M usaUSA
Accelerate Diagnostics Accelerate Diagnostics
AXDX
- -61.36 % $ 2.46 M usaUSA
Mettler-Toledo International Mettler-Toledo International
MTD
$ 1 303.47 -1.63 % $ 26.9 B schweizSchweiz
Global Cord Blood Corporation Global Cord Blood Corporation
CO
- - $ 399 M chinaChina
Myriad Genetics Myriad Genetics
MYGN
$ 4.96 -1.0 % $ 459 M usaUSA
Fluidigm Corporation Fluidigm Corporation
FLDM
- 1.08 % $ 308 M usaUSA
Genetic Technologies Limited Genetic Technologies Limited
GENE
- - $ 7.1 B australiaAustralia
NeoGenomics NeoGenomics
NEO
$ 9.08 -4.42 % $ 1.16 B usaUSA
Genetron Holdings Limited Genetron Holdings Limited
GTH
- 0.12 % $ 80.1 M chinaChina
Natera Natera
NTRA
$ 198.57 -0.8 % $ 19.5 B usaUSA
PRA Health Sciences, Inc. PRA Health Sciences, Inc.
PRAH
- - $ 10.7 B usaUSA
Pacific Biosciences of California Pacific Biosciences of California
PACB
$ 1.51 -7.1 % $ 453 M usaUSA
Biodesix Biodesix
BDSX
$ 15.96 1.33 % $ 2.07 B usaUSA
Precipio Precipio
PRPO
$ 24.47 -0.85 % $ 31.8 M usaUSA
Biocept Biocept
BIOC
- -13.05 % $ 7.29 M usaUSA
BioNano Genomics BioNano Genomics
BNGO
$ 1.09 -4.17 % $ 1.39 M usaUSA
Quest Diagnostics Incorporated Quest Diagnostics Incorporated
DGX
$ 205.94 -2.05 % $ 22.9 B usaUSA
Danaher Corporation Danaher Corporation
DHR
$ 201.72 -2.03 % $ 144 B usaUSA
Senseonics Holdings Senseonics Holdings
SENS
$ 7.65 -7.64 % $ 319 M usaUSA
Sotera Health Company Sotera Health Company
SHC
$ 15.56 -2.16 % $ 4.42 B usaUSA
Soleno Therapeutics Soleno Therapeutics
SLNO
$ 37.76 -3.33 % $ 1.92 B usaUSA
Exact Sciences Corporation Exact Sciences Corporation
EXAS
$ 103.23 -0.12 % $ 19.5 B usaUSA
Bioventus Bioventus
BVS
$ 8.69 -0.91 % $ 544 M usaUSA
DarioHealth Corp. DarioHealth Corp.
DRIO
$ 10.55 -1.86 % $ 299 M israelIsrael
DexCom DexCom
DXCM
$ 73.46 -0.43 % $ 28.7 B usaUSA
Thermo Fisher Scientific Thermo Fisher Scientific
TMO
$ 501.43 -1.38 % $ 189 B usaUSA
QIAGEN N.V. QIAGEN N.V.
QGEN
- - $ 10.6 B niderlandNiderland
Burning Rock Biotech Limited Burning Rock Biotech Limited
BNR
$ 24.2 -3.82 % $ 258 M chinaChina
Twist Bioscience Corporation Twist Bioscience Corporation
TWST
$ 44.79 -2.4 % $ 2.68 B usaUSA
CareDx, Inc CareDx, Inc
CDNA
$ 18.19 -2.96 % $ 969 M usaUSA
VolitionRx Limited VolitionRx Limited
VNRX
$ 0.2 -3.15 % $ 19.2 M singaporeSingapore
Chembio Diagnostics Chembio Diagnostics
CEMI
- 0.22 % $ 16.8 M usaUSA
Waters Corporation Waters Corporation
WAT
$ 306.49 -0.21 % $ 18.3 B usaUSA
Check-Cap Ltd. Check-Cap Ltd.
CHEK
- - $ 9.42 M israelIsrael
Guardant Health Guardant Health
GH
$ 90.69 -1.67 % $ 11.4 B usaUSA
IQVIA Holdings IQVIA Holdings
IQV
$ 171.73 -1.46 % $ 29.5 B usaUSA